AU2012325941A1 - Method of treating or reducing EFP - Google Patents

Method of treating or reducing EFP Download PDF

Info

Publication number
AU2012325941A1
AU2012325941A1 AU2012325941A AU2012325941A AU2012325941A1 AU 2012325941 A1 AU2012325941 A1 AU 2012325941A1 AU 2012325941 A AU2012325941 A AU 2012325941A AU 2012325941 A AU2012325941 A AU 2012325941A AU 2012325941 A1 AU2012325941 A1 AU 2012325941A1
Authority
AU
Australia
Prior art keywords
collagenase
administered
injection
efp
injections
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2012325941A
Other languages
English (en)
Inventor
Susan G. Emeigh Hart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Auxilium International Holdings Inc
Original Assignee
Auxilium International Holdings Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Auxilium International Holdings Inc filed Critical Auxilium International Holdings Inc
Publication of AU2012325941A1 publication Critical patent/AU2012325941A1/en
Priority to AU2016202026A priority Critical patent/AU2016202026A1/en
Priority to AU2017248451A priority patent/AU2017248451B2/en
Priority to AU2020200763A priority patent/AU2020200763B2/en
Priority to AU2022202987A priority patent/AU2022202987B2/en
Priority to AU2025204462A priority patent/AU2025204462A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/64—Proteins; Peptides; Derivatives or degradation products thereof
    • A61K8/66—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0021—Intradermal administration, e.g. through microneedle arrays or needleless injectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/04—Drugs for skeletal disorders for non-specific disorders of the connective tissue
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A61Q19/06—Preparations for care of the skin for countering cellulitis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24003—Microbial collagenase (3.4.24.3)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/74—Biological properties of particular ingredients
    • A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/91—Injection

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Birds (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2012325941A 2011-10-21 2012-10-19 Method of treating or reducing EFP Abandoned AU2012325941A1 (en)

Priority Applications (5)

Application Number Priority Date Filing Date Title
AU2016202026A AU2016202026A1 (en) 2011-10-21 2016-03-31 Method of treating or reducing efp
AU2017248451A AU2017248451B2 (en) 2011-10-21 2017-10-17 Method of treating or reducing efp
AU2020200763A AU2020200763B2 (en) 2011-10-21 2020-02-03 Method of treating or reducing efp
AU2022202987A AU2022202987B2 (en) 2011-10-21 2022-05-04 Method of treating or reducing efp
AU2025204462A AU2025204462A1 (en) 2011-10-21 2025-06-16 Method of treating or reducing efp

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161549863P 2011-10-21 2011-10-21
US61/549,863 2011-10-21
PCT/US2012/061063 WO2013059619A1 (en) 2011-10-21 2012-10-19 Method of treating or reducing efp

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2016202026A Division AU2016202026A1 (en) 2011-10-21 2016-03-31 Method of treating or reducing efp

Publications (1)

Publication Number Publication Date
AU2012325941A1 true AU2012325941A1 (en) 2014-05-15

Family

ID=48141393

Family Applications (6)

Application Number Title Priority Date Filing Date
AU2012325941A Abandoned AU2012325941A1 (en) 2011-10-21 2012-10-19 Method of treating or reducing EFP
AU2016202026A Abandoned AU2016202026A1 (en) 2011-10-21 2016-03-31 Method of treating or reducing efp
AU2017248451A Active AU2017248451B2 (en) 2011-10-21 2017-10-17 Method of treating or reducing efp
AU2020200763A Active AU2020200763B2 (en) 2011-10-21 2020-02-03 Method of treating or reducing efp
AU2022202987A Active AU2022202987B2 (en) 2011-10-21 2022-05-04 Method of treating or reducing efp
AU2025204462A Pending AU2025204462A1 (en) 2011-10-21 2025-06-16 Method of treating or reducing efp

Family Applications After (5)

Application Number Title Priority Date Filing Date
AU2016202026A Abandoned AU2016202026A1 (en) 2011-10-21 2016-03-31 Method of treating or reducing efp
AU2017248451A Active AU2017248451B2 (en) 2011-10-21 2017-10-17 Method of treating or reducing efp
AU2020200763A Active AU2020200763B2 (en) 2011-10-21 2020-02-03 Method of treating or reducing efp
AU2022202987A Active AU2022202987B2 (en) 2011-10-21 2022-05-04 Method of treating or reducing efp
AU2025204462A Pending AU2025204462A1 (en) 2011-10-21 2025-06-16 Method of treating or reducing efp

Country Status (14)

Country Link
US (2) US20140335072A1 (https=)
EP (2) EP3581199B1 (https=)
JP (4) JP2014530873A (https=)
AU (6) AU2012325941A1 (https=)
BR (1) BR112014009785B1 (https=)
CA (1) CA2852942C (https=)
DK (2) DK2768523T3 (https=)
ES (2) ES2953560T3 (https=)
FI (1) FI3581199T3 (https=)
HU (2) HUE044650T2 (https=)
MX (2) MX2014004792A (https=)
PL (1) PL3581199T3 (https=)
PT (2) PT3581199T (https=)
WO (1) WO2013059619A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2802652T (pt) 2012-01-12 2019-09-10 Endo Global Ventures Enzimas de clostridium histolyticum
BR112014027347A2 (pt) 2012-05-01 2017-06-27 Proteolease Ltd método para extrair um dente em um sujeito com essa necessidade, método para substituir um dente com um implante dentário e kit para extrair um dente
EP3834840B8 (en) 2013-03-15 2025-09-17 Endo Biologics Limited Treatment method and product for uterine fibroids using purified collagenase
CN103751102A (zh) * 2014-01-15 2014-04-30 上海交通大学 一种胶原酶温敏水凝胶及其制备方法和应用
EP4591945A3 (en) 2017-03-01 2026-04-15 Endo Operations Limited Apparatus and method for assessing and treating cellulite
JP7227918B2 (ja) 2017-03-28 2023-02-22 エンド ベンチャーズ リミテッド コラゲナーゼ産生の改良された方法
WO2020021330A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
WO2020021332A2 (en) * 2018-07-12 2020-01-30 Endo Global Aesthetics Limited Injection techniques for the treatment of cellulite
BR112021001186A8 (pt) 2018-07-23 2023-01-10 Nc8 Inc Aparelho e sistema para o tratamento de celulite e uso de um sistema para o tratamento de celulite para tratar expressões de celulite na pele de um paciente
MX2021000901A (es) * 2018-07-23 2021-06-18 Revelle Aesthetics Inc Sistema y metodos de tratamiento de celulitis.
US20240277595A1 (en) * 2018-09-18 2024-08-22 Endo Global Aesthetics Limited Compositions and methods for treating cellulite
US20220305094A1 (en) * 2019-01-06 2022-09-29 Endo Global Aesthetics Limited Collagenase formulations and methods of producing the same
JP7849880B2 (ja) 2019-09-06 2026-04-22 リベル・エスセティクス・インコーポレイテッド セルライト治療システムおよび方法
US11872267B2 (en) 2019-10-15 2024-01-16 The Johns Hopkins University Treatment of uterine fibroids using purified collagenase
EP3861948A1 (en) * 2020-02-10 2021-08-11 Daniel A. Del Vecchio Cellulite eradication methods
CA3216691A1 (en) * 2021-04-16 2022-10-20 H. Lee Moffitt Cancer Center And Research Institute, Inc. Culture of tumor infiltrating lymphocytes from tumor digest

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4524065A (en) * 1983-08-04 1985-06-18 Bio-Specifics N.V. Method for the prevention and treatment of scars with enzymes
US4645668A (en) 1983-08-04 1987-02-24 Biospecifics, Nv Method for the prevention and treatment of scars with enzymes
US6958150B2 (en) * 1994-12-15 2005-10-25 Advance Biofactures Of Curacao, N.V. Reduction of adipose tissue
ES2660172T3 (es) * 2004-05-19 2018-03-21 Los Angeles Biomedical Research Institute At Harbor-Ucla Medical Center Composición inyectable que comprende desoxicolato de sodio
US20070224184A1 (en) 2006-02-22 2007-09-27 The Research Foundation Of The State University Of New York Method for treating cellulite
US7811560B2 (en) * 2006-01-30 2010-10-12 Auxilium Us Holdings, Llc Compositions and methods for treating collagen-mediated diseases
WO2007100590A2 (en) * 2006-02-22 2007-09-07 Auxilium Pharmaceuticals, Inc. Methods for treating cellulite
WO2008101406A1 (en) * 2007-02-14 2008-08-28 Yolare Dermaceuticals, Llc Modified mutant collagenase and it's use in fat melting and in scar reduction

Also Published As

Publication number Publication date
HUE063599T2 (hu) 2024-01-28
AU2017248451B2 (en) 2019-11-14
ES2741476T3 (es) 2020-02-11
JP2022123073A (ja) 2022-08-23
MX2014004792A (es) 2015-08-14
JP2020158521A (ja) 2020-10-01
AU2017248451A1 (en) 2017-11-02
EP3581199A1 (en) 2019-12-18
US20240216485A1 (en) 2024-07-04
JP2024123126A (ja) 2024-09-10
NZ624057A (en) 2016-08-26
BR112014009785A8 (pt) 2020-02-27
AU2020200763A1 (en) 2020-02-20
EP3581199B1 (en) 2023-05-31
DK2768523T3 (da) 2019-07-22
PL3581199T3 (pl) 2023-09-11
NZ759819A (en) 2020-11-27
NZ737403A (en) 2020-05-29
PT3581199T (pt) 2023-08-31
HK1201439A1 (en) 2015-09-04
EP2768523A4 (en) 2015-04-22
EP2768523B1 (en) 2019-05-22
US20140335072A1 (en) 2014-11-13
FI3581199T3 (fi) 2023-08-18
ES2953560T3 (es) 2023-11-14
MX2019007779A (es) 2019-09-04
AU2025204462A1 (en) 2025-07-03
JP2018027968A (ja) 2018-02-22
NZ722722A (en) 2019-05-31
AU2016202026A1 (en) 2016-04-21
WO2013059619A1 (en) 2013-04-25
HUE044650T2 (hu) 2019-11-28
NZ769098A (en) 2022-03-25
EP2768523A1 (en) 2014-08-27
PT2768523T (pt) 2019-08-29
AU2022202987B2 (en) 2025-03-20
MX392388B (es) 2025-03-24
CA2852942A1 (en) 2013-04-25
AU2020200763B2 (en) 2022-05-26
DK3581199T3 (da) 2023-09-04
BR112014009785A2 (pt) 2017-04-25
BR112014009785B1 (pt) 2020-06-30
CA2852942C (en) 2023-01-10
JP2014530873A (ja) 2014-11-20
AU2022202987A1 (en) 2022-05-26

Similar Documents

Publication Publication Date Title
AU2022202987B2 (en) Method of treating or reducing efp
JP6649449B2 (ja) セルライト処置用コラゲナーゼ
EP3932938A1 (en) Botulinum toxin type a complex, and formulation thereof and usage method therefor
CN101405023A (zh) 治疗脂肪团的方法
HK40020065B (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
HK40020065A (en) Methods of treatment or reduction of edematous-fibrosclerotic panniculopathy
NZ624057B2 (en) Method of treating or reducing efp
NZ737403B2 (en) Method of treating or reducing efp
HK1201439B (en) Method of treating or reducing efp
NZ769098B2 (en) Method of treating or reducing efp
NZ722722B2 (en) Method of treating or reducing efp
NZ759819B2 (en) Method of treating or reducing efp
TWI739368B (zh) A型肉毒桿菌毒素複合物、其配製劑和使用方法

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted